STILLA

法国Stilla Technologies公司位于法国巴黎Villejuif生物园，成立于2013年，专注于开发新一代、高分辨率的基因检测工具，其产品Naica™ Crystal微滴数字PCR系统是市场上操作最简便、而且是唯一一款同时实现三色检测的数字PCR系统，为生物研究人员提供快捷、精准的核酸绝对定量工具。

Naica™ Crystal微滴数字PCR系统采用独有的cutting-edge微流体创新型2DSapphire芯片作为整个系统的设计核心，仅需将PCR预混液加入Sapphire芯片中，即可完成从微滴生成、扩增和分析的整个过程。结合强大的图像分析和直观可视的软件分析，获得卓越的置信水平和真实可信的数据结果。“在进行核酸绝对定量时，数字PCR技术因其极高的灵敏度，充分弥补了依靠Ct值（Real Time PCR技术）不能达到很好分辨效果的应用领域，例如痕量核酸检测、稀有突变检测、拷贝数变异、单细胞基因表达分析等，而这些检测结果对医学研究有极为重要的意义，特别是在液态活检（cfDNA）、传染病检测、癌症早期诊断、预后和随诊、以及器官移植等方面。”Stilla Technologies公司创始人Remi Dangla博士如是说。

Remi Dangla博士在美国MIT（麻省理工学院，被誉为“世界理工大学”之最）获得博士学位，并获得“2014 innovator under35称号”，本人获得多项物理学、物理化学等多项专利，携Stilla Technologies公司，与美国MIT和法国癌症研究中心保持长期合作，为生物、医学等领域科学家提供最佳解决方案。

Stilla technologies, located in Villejuif Biological Park, Paris, France, was founded in 2013, focusing on the development of a new generation and high-resolution gene detection tool, its product Naica ™  Crystal droplet digital PCR system is the most convenient and the only digital PCR system to realize three-color detection at the same time in the market. It provides biological researchers with a fast and accurate absolute quantitative tool for nucleic acid.

 Naica ™  Crystal droplet digital PCR system uses the unique cutting edge microfluidic innovative 2dsapphire chip as the design core of the whole system. The whole process of droplet generation, amplification and analysis can be completed only by adding PCR premix to sapphire chip. Combined with powerful image analysis and intuitive and visual software analysis, excellent confidence level and authentic data results are obtained“ In the absolute quantification of nucleic acids, digital PCR technology, due to its high sensitivity, fully makes up for the application fields that can not achieve good resolution by relying on CT value (real time PCR technology), such as trace nucleic acid detection, rare mutation detection, copy number variation, single cell gene expression analysis, etc. These detection results are of great significance to medical research, Especially in liquid biopsy (cfdna), infectious disease detection, early cancer diagnosis, prognosis and follow-up, and organ transplantation. " Said Dr. Remi dangla, founder of stilla technologies.

 Dr. Remi dangla received his doctorate from MIT (Massachusetts Institute of technology, known as the "world's most Polytechnic University") and won the "2014 innovator under35 title". I have won a number of patents in physics, physical chemistry and other fields. With stilla technologies, I have maintained long-term cooperation with MIT and the French cancer research center to provide services for biology Scientists in fields such as medicine provide the best solutions.